We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q3
Read MoreHide Full Article
Myriad Genetics, Inc. (MYGN - Free Report) reported adjusted earnings per share (EPS) of 31 cents in the third quarter of fiscal 2018, up 14.8% year over year. Moreover, adjusted EPS beat the Zacks Consensus Estimate of 27 cents and exceeded the company’s guided range of 26-28 cents.
Reported earnings came in at 16 cents, compared with 6 cents a year ago.
Revenues
Total revenues were down 1.7% year over year to $193.5 million in the quarter under review. The figure however outpaced the Zacks Consensus Estimate of $187.9 million and was above the company’s guidance of $186-$188 million. The year-over-year decline was however caused by price reductions in long-term contracts related to Hereditary cancer testing.
Further, the company believes unfavorable weather conditions across the United States had an adverse impact of around 1-2% on third-quarter test volumes.
However, the decline was partially offset by growing new product volumes, better-than-expected hereditary cancer volumes and the success of the company’s Elevate 2020 program. Moreover, this was the fifth consecutive quarter in which the company witnessed year-over-year Hereditary cancer volume growth led by encouraging response to the newly-launched riskScore test under its myRisk Hereditary Cancer testing portfolio.
Myriad Genetics, Inc. Price, Consensus and EPS Surprise
Segment-wise, Molecular diagnostic tests (92.9% of total revenue) recorded total revenues of $179.7 million, down 3% year over year on account of a 12.4% decline in Hereditary cancer testing revenues to $123.3 million. Also, Hereditary Cancer testing revenues declined due to price reductions in long-term contracts. However, volume growth exceeded the company’s 3% growth target on a year-over-year basis.
EndoPredict testing revenues remained flat year over year at $2.3 million in the reported quarter. Vectra DA testing revenues came in at $15 million, up 33.9% year over year, while other testing revenues declined 38.9% to $2.2 million. Further, GeneSight testing revenues rose 27.2% year over year to $30.4 million in the reported quarter. Prolaris tests raked in revenues of $6.5 million in the quarter, up 91.2% year over year.
Pharmaceutical and clinical service revenues (accounting for the rest) in the quarter totaled $13.8 million, reflecting a year-over-year increase of 17.9%.
Margin Trends
Gross margin in the quarter under review contracted 30 basis points (bps) to 77.2%. According to management, the gross margin performance was affected by Hereditary Cancer test pricing issue, partially offset by improved efficiencies in production process a result of the Elevate 2020 program and rising new product reimbursements for Vectra DA and Prolaris tests.
Operating expenses contracted 4.4% to $133.6 million as a 5.1% rise in research and development (R&D) expenses (to $18.5 million) was offset by a 5.7% fall in selling, general and administrative (SG&A) expenses (to $115.1 million) in the reported quarter.
Financial Position
Myriad Genetics exited the fiscal third quarter with cash, cash equivalents and marketable securities of $157.3 million, compared with $143.5 million at the end of the preceding quarter. Year to date, cash flow from operations totaled $68 million, compared with $69.6 million a year ago. Year to date, the company registered free cash flow of $61.4 million, compared with $64.2 million in the year-ago period.
Guidance
Myriad Genetics has raised the guidance for fiscal 2018 revenues to $771-$773 million from $760-$770 million. The Zacks Consensus Estimate of $774.4 million lies above the guided range.
On the bottom-line front, the company lifted the adjusted EPS range to $1.19-$1.21 from $1.11-$1.16. The current Zacks Consensus Estimate of $1.16 is below the company’s guided range.
Management has provided the guidance for the fourth quarter of fiscal 2018. The company estimates adjusted EPS of 31-33 cents on total revenues of $193-$195 million. The Zacks Consensus Estimate for adjusted EPS is 31 cents and revenues is $197.8 million. While the consensus estimate for earnings coincides with the low end of the company’s guided range, our revenue estimate lies above the projected range.
Our View
Myriad Genetics performed better than expected in third-quarter fiscal 2018. However, the year-over-year decline in revenues is disappointing. On a positive note, the company observed strong growth in both GeneSight, Vectra DA and Prolaris testing revenues. The recent FDA approvals and encouraging test results buoy optimism.
On the flip side, unfavorable foreign currency translation continues to pose a threat. With a considerable portion of its revenues coming from outside the United States, the company faces the risk of exchange rate fluctuations.
Zacks Rank & Other Key Picks
Myriad Genetics has a Zacks Rank #2 (Buy).
Other top-ranked stocks in the broader medical space which have reported solid results this season are Intuitive Surgical (ISRG - Free Report) , Chemed Corporation (CHE - Free Report) and Baxter International Inc. (BAX - Free Report) . While Intuitive Surgical sports a Zacks Rank #1 (Strong Buy), Chemed and Baxter carry a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Intuitive Surgical reported first-quarter 2018 adjusted EPS of $2.44, which beat the Zacks Consensus Estimate by 22.6%. Revenues totaled $848 million, also surpassing the consensus estimate by 10.6%.
Chemed posted first-quarter 2018 adjusted EPS of $2.72, surpassing the Zacks Consensus Estimate of $2.37. Revenues came in at $439.2 million, beating the Zacks Consensus Estimate of $420 million.
Baxter posted first-quarter 2018 adjusted EPS of 70 cents, which beat the Zacks Consensus Estimate by 12.9%. Revenues of $2.68 billion edged past the Zacks Consensus Estimate of $2.62 billion.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q3
Myriad Genetics, Inc. (MYGN - Free Report) reported adjusted earnings per share (EPS) of 31 cents in the third quarter of fiscal 2018, up 14.8% year over year. Moreover, adjusted EPS beat the Zacks Consensus Estimate of 27 cents and exceeded the company’s guided range of 26-28 cents.
Reported earnings came in at 16 cents, compared with 6 cents a year ago.
Revenues
Total revenues were down 1.7% year over year to $193.5 million in the quarter under review. The figure however outpaced the Zacks Consensus Estimate of $187.9 million and was above the company’s guidance of $186-$188 million. The year-over-year decline was however caused by price reductions in long-term contracts related to Hereditary cancer testing.
Further, the company believes unfavorable weather conditions across the United States had an adverse impact of around 1-2% on third-quarter test volumes.
However, the decline was partially offset by growing new product volumes, better-than-expected hereditary cancer volumes and the success of the company’s Elevate 2020 program. Moreover, this was the fifth consecutive quarter in which the company witnessed year-over-year Hereditary cancer volume growth led by encouraging response to the newly-launched riskScore test under its myRisk Hereditary Cancer testing portfolio.
Myriad Genetics, Inc. Price, Consensus and EPS Surprise
Myriad Genetics, Inc. Price, Consensus and EPS Surprise | Myriad Genetics, Inc. Quote
Quarter in Details
Segment-wise, Molecular diagnostic tests (92.9% of total revenue) recorded total revenues of $179.7 million, down 3% year over year on account of a 12.4% decline in Hereditary cancer testing revenues to $123.3 million. Also, Hereditary Cancer testing revenues declined due to price reductions in long-term contracts. However, volume growth exceeded the company’s 3% growth target on a year-over-year basis.
EndoPredict testing revenues remained flat year over year at $2.3 million in the reported quarter. Vectra DA testing revenues came in at $15 million, up 33.9% year over year, while other testing revenues declined 38.9% to $2.2 million. Further, GeneSight testing revenues rose 27.2% year over year to $30.4 million in the reported quarter. Prolaris tests raked in revenues of $6.5 million in the quarter, up 91.2% year over year.
Pharmaceutical and clinical service revenues (accounting for the rest) in the quarter totaled $13.8 million, reflecting a year-over-year increase of 17.9%.
Margin Trends
Gross margin in the quarter under review contracted 30 basis points (bps) to 77.2%. According to management, the gross margin performance was affected by Hereditary Cancer test pricing issue, partially offset by improved efficiencies in production process a result of the Elevate 2020 program and rising new product reimbursements for Vectra DA and Prolaris tests.
Operating expenses contracted 4.4% to $133.6 million as a 5.1% rise in research and development (R&D) expenses (to $18.5 million) was offset by a 5.7% fall in selling, general and administrative (SG&A) expenses (to $115.1 million) in the reported quarter.
Financial Position
Myriad Genetics exited the fiscal third quarter with cash, cash equivalents and marketable securities of $157.3 million, compared with $143.5 million at the end of the preceding quarter. Year to date, cash flow from operations totaled $68 million, compared with $69.6 million a year ago. Year to date, the company registered free cash flow of $61.4 million, compared with $64.2 million in the year-ago period.
Guidance
Myriad Genetics has raised the guidance for fiscal 2018 revenues to $771-$773 million from $760-$770 million. The Zacks Consensus Estimate of $774.4 million lies above the guided range.
On the bottom-line front, the company lifted the adjusted EPS range to $1.19-$1.21 from $1.11-$1.16. The current Zacks Consensus Estimate of $1.16 is below the company’s guided range.
Management has provided the guidance for the fourth quarter of fiscal 2018. The company estimates adjusted EPS of 31-33 cents on total revenues of $193-$195 million. The Zacks Consensus Estimate for adjusted EPS is 31 cents and revenues is $197.8 million. While the consensus estimate for earnings coincides with the low end of the company’s guided range, our revenue estimate lies above the projected range.
Our View
Myriad Genetics performed better than expected in third-quarter fiscal 2018. However, the year-over-year decline in revenues is disappointing. On a positive note, the company observed strong growth in both GeneSight, Vectra DA and Prolaris testing revenues. The recent FDA approvals and encouraging test results buoy optimism.
On the flip side, unfavorable foreign currency translation continues to pose a threat. With a considerable portion of its revenues coming from outside the United States, the company faces the risk of exchange rate fluctuations.
Zacks Rank & Other Key Picks
Myriad Genetics has a Zacks Rank #2 (Buy).
Other top-ranked stocks in the broader medical space which have reported solid results this season are Intuitive Surgical (ISRG - Free Report) , Chemed Corporation (CHE - Free Report) and Baxter International Inc. (BAX - Free Report) . While Intuitive Surgical sports a Zacks Rank #1 (Strong Buy), Chemed and Baxter carry a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Intuitive Surgical reported first-quarter 2018 adjusted EPS of $2.44, which beat the Zacks Consensus Estimate by 22.6%. Revenues totaled $848 million, also surpassing the consensus estimate by 10.6%.
Chemed posted first-quarter 2018 adjusted EPS of $2.72, surpassing the Zacks Consensus Estimate of $2.37. Revenues came in at $439.2 million, beating the Zacks Consensus Estimate of $420 million.
Baxter posted first-quarter 2018 adjusted EPS of 70 cents, which beat the Zacks Consensus Estimate by 12.9%. Revenues of $2.68 billion edged past the Zacks Consensus Estimate of $2.62 billion.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>